Crinecerfont free base · Synonyms: SSR-125543

Crinecerfont is a potent, orally active, non-peptide CRF1 receptor antagonist.

For research use only. Not for human or veterinary use.

Target CFTR

Research area Metabolic Disease

Purity >98% Stock Inquire

Data Sheet SDS COA

Crinecerfont structure

CAS No.: 752253-39-7

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
1 g	USD 685.00	BP-02082-1g	In stock	Get quote
2 g	USD 1,185.00	BP-02082-2g	In stock	Get quote
5 g	Inquire	BP-02082-5g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

Crinecerfont (SSR-125543) is a potent, orally active, non-peptide CRF1 receptor antagonist. Crinecerfont can be used for Classic congenital adrenal hyperplasia (CAH) research. Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Biological activity

In Vivo Crinecerfont (SSR-125543) (20 mg/kg; i.p.; daily; 5 weeks) improves hypothalamic-pituitary-adrenal (HPA) axis negative feedback sensitivity in chronically stressed mice but exacerbates their basal circadian corticosterone secretion, and does not alter HPA axis circadian activity or negative feedback sensitivity in non-stressed control mice.

Identifiers

SMILES: C#CCN(C1=NC(C2=C(C=C(C(C)=C2)OC)Cl)=C(S1)C)[C@H](C3=CC(F)=C(C=C3)C)CC4CC4
InChIKey: IEAKXXNRGSLYTQ-DEOSSOPVSA-N

Specifications

MW (average): 483.0400
Formula: C₂₇H₂₈ClFN₂OS
CAS No.: 752253-39-7
Physical state: Solid
Color: Light yellow to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃, 3 years; 4℃, 2 years; In solvent -20℃, 1 month;

Solubility

soluble in DMSO

Documents

References

[1]. Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia (CAHtalyst).

[2]. Ibarguen-Vargas Y, et al. CRF-R1 Antagonist Treatment Exacerbates Circadian Corticosterone Secretion under Chronic Stress, but Preserves HPA Feedback Sensitivity. Pharmaceutics. 2021;13(12):2114. Published 2021 Dec 8.

[3]. Newfield RS, et al. Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2023;108(11):2871-2878.

Same target

Search CFTR

Same research area

Search Metabolic Disease